



Sydney, Australia. 21 June, 2017.

PHEBRA STATEMENT REGARDING US SUPPLY AGREEMENT FOR CRITICAL MEDICINE

Australian pharmaceutical manufacturer Phebra has entered into a commercial agreement to supply Sodium Bicarbonate Injection to the US to assist with a shortage in the US hospital market.

Phebra has increased production at its new manufacturing plant at Lane Cove West in Sydney to meet the unanticipated demand from the US.

Phebra is manufacturing the Sodium Bicarbonate Injection under contract for a US supplier and is not responsible for price setting in the US market.

Phebra remains firmly committed to manufacturing and supplying Sodium Bicarbonate Injection and other critical medicines to the Australian healthcare system.

Phebra wishes to emphasise that the US manufacturing agreement will not impact on Phebra's manufacture and supply of Sodium Bicarbonate Injection to the Australian market.

Phebra CEO, Dr Mal Eutick, said the company was pleased that it was able to respond quickly to alleviate the critical shortage of the medicine in the US.

About Phebra

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, North America and parts of Europe.

At Phebra, we create critical medicines that save and improve lives.

Phebra media contact: Richard Lenarduzzi. 0411 254 390